AR and metastatic prostate carcinoma: The PROTACs technology was first proposed by Professor Craig Crew’s team at Yale University in 2001 (189); in 2008, the team reported the first small molecule PROTACs that successfully targeted the androgen receptor (190); in 2019, the first PROTACs drugs entered human trials: ARV-110 (Phase I/II, NCT03888612), targeting the androgen receptor (AR), for metastatic prostate cancer (128); ARV-471 (Phase I/II, NCT04072952), targeting the estrogen receptor (ER), for ER+/HER2- metastatic breast cancer (191).